Interferon-Inducible Protein IFIXα1 Functions as a Negative Regulator of HDM2

REFERENCES

• Albrecht, M., D. Choubey, and T. Lengauer. 2005. The HIN domain of IFI-200 proteins consists of two OB folds. Biochem. Biophys. Res. Commun. 327:679–687.
   PubMedGoogle Scholar
• Asefa, B., K. D. Klarmann, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, and J. R. Keller. 2004. The interferon-inducible negative regulator of cell growth. Blood Cells Mol. Dis. 32:155–167.
   PubMed Web of Science ®Google Scholar
• Azzimonti, B., M. Pagano, M. Mondini, M. De Andrea, G. Valente, G. Monga, M. Tommasino, P. Aluffi, S. Landolfo, and M. Gariglio. 2004. Altered patterns of the interferon-inducible gene IFI16 expression in head and neck squamous cell carcinoma: immunohistochemical study including correlation with retinoblastoma protein, human papillomavirus infection and proliferation index. Histopathology 45:560–572.
   PubMed Web of Science ®Google Scholar
• Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461–468.
   PubMed Web of Science ®Google Scholar
• Biron, C. A., and G. C. Sen. 2001. Interferons and other cytokines, p. 321–351. In D. M. Knipe, P. M. Howley, D. E. Griffin, et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
   Google Scholar
• Bochkarev, A., and E. Bochkareva. 2004. From RPA to BRCA2: lessons from single-stranded DNA binding by the OB-fold. Curr. Opin. Struct. Biol. 14:36–42.
   PubMed Web of Science ®Google Scholar
• Boyd, S. D., K. Y. Tsai, and T. Jacks. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:563–568.
   PubMed Web of Science ®Google Scholar
• Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501.
   PubMed Web of Science ®Google Scholar
• Buschmann, T., D. Lerner, C. G. Lee, and Z. Ronai. 2001. The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9. J. Biol. Chem. 276:40389–40395.
   PubMedGoogle Scholar
• Chau, V., J. W. Tobias, A. Bachmair, D. Marriott, D. J. Ecker, D. K. Gonda, and A. Varshavsky. 1989. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243:1576–1583.
   PubMed Web of Science ®Google Scholar
• Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107–4114.
   PubMed Web of Science ®Google Scholar
• Choubey, D., and B. L. Kotzin. 2002. Interferon-inducible p202 in the susceptibility to systemic lupus. Front. Biosci. 7:e252–e262.
   PubMedGoogle Scholar
• Cuddihy, A. R., S. Li, N. W. N. Tam, A. H.-T. Wong, Y. Taya, N. Abraham, J. C. Bell, and A. E. Koromilas. 1999. Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol. Cell. Biol. 19:2475–2484.
   PubMed Web of Science ®Google Scholar
• Cuddihy, A. R., A. H. Wong, N. W. Tam, S. Li, and A. E. Koromilas. 1999. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 18:2690–2702.
   PubMed Web of Science ®Google Scholar
• Datta, B., B. Li, D. Choubey, G. Nallur, and P. Lengyel. 1996. p202, an interferon-inducible modulator of transcription, inhibits transcriptional activation by the p53 tumor suppressor protein, and a segment from the p53-binding protein 1 that binds to p202 overcomes this inhibition. J. Biol. Chem. 271:27544–27555.
   PubMedGoogle Scholar
• Deb, S. P. 2003. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol. Cancer Res. 1:1009–1016.
   PubMed Web of Science ®Google Scholar
• DeYoung, K. L., M. E. Ray, Y. A. Su, S. L. Anzick, R. W. Johnstone, J. A. Trapani, P. S. Meltzer, and J. M. Trent. 1997. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 15:453–457.
   PubMed Web of Science ®Google Scholar
• Ding, Y., L. Wang, L. K. Su, J. A. Frey, R. Shao, K. K. Hunt, and D. H. Yan. 2004. Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer. Oncogene 23:4556–4566.
   PubMed Web of Science ®Google Scholar
• Doggett, K. L., J. A. Briggs, M. F. Linton, S. Fazio, D. R. Head, J. Xie, Y. Hashimoto, J. Laborda, and R. C. Briggs. 2002. Retroviral mediated expression of the human myeloid nuclear antigen in a null cell line upregulates Dlk1 expression. J. Cell. Biochem. 86:56–66.
   PubMedGoogle Scholar
• Duthu, A., B. Debuire, J. Romano, J. C. Ehrhart, M. Fiscella, E. May, E. Appella, and P. May. 1992. p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene 7:2161–2167.
   PubMedGoogle Scholar
• el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Fakharzadeh, S. S., S. P. Trusko, and D. L. George. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565–4569.
   PubMed Web of Science ®Google Scholar
• Fang, S., J. P. Jensen, R. L. Ludwig, K. H. Vousden, and A. M. Weissman. 2000. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:8945–8951.
   PubMed Web of Science ®Google Scholar
• Finlay, C. A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13:301–306.
   PubMed Web of Science ®Google Scholar
• Fischer, P. M., and D. P. Lane. 2004. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol. Sci. 25:343–346.
   PubMedGoogle Scholar
• Fujiuchi, N., J. A. Aglipay, T. Ohtsuka, N. Maehara, F. Sahin, G. H. Su, S. W. Lee, and T. Ouchi. 2004. Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J. Biol. Chem. 279:20339–20344.
   PubMedGoogle Scholar
• Gariglio, M., B. Azzimonti, M. Pagano, G. Palestro, M. De Andrea, G. Valente, G. Voglino, L. Navino, and S. Landolfo. 2002. Immunohistochemical expression analysis of the human interferon-inducible gene IFI16, a member of the HIN200 family, not restricted to hematopoietic cells. J. Interferon Cytokine Res. 22:815–821.
   PubMedGoogle Scholar
• Geyer, R. K., Z. K. Yu, and C. G. Maki. 2000. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2:569–573.
   PubMed Web of Science ®Google Scholar
• Gooch, J. L., R. E. Herrera, and D. Yee. 2000. The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth Differ. 11:335–342.
   PubMedGoogle Scholar
• Grossman, S. R., M. E. Deato, C. Brignone, H. M. Chan, A. L. Kung, H. Tagami, Y. Nakatani, and D. M. Livingston. 2003. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300:342–344.
   PubMed Web of Science ®Google Scholar
• Grossman, S. R., M. Perez, A. L. Kung, M. Joseph, C. Mansur, Z. X. Xiao, S. Kumar, P. M. Howley, and D. M. Livingston. 1998. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2:405–415.
   PubMed Web of Science ®Google Scholar
• Gu, J., H. Kawai, L. Nie, H. Kitao, D. Wiederschain, A. G. Jochemsen, J. Parant, G. Lozano, and Z. M. Yuan. 2002. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277:19251–19254.
   PubMed Web of Science ®Google Scholar
• Gudas, J. M., H. Nguyen, R. C. Klein, D. Katayose, P. Seth, and K. H. Cowan. 1995. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin. Cancer Res. 1:71–80.
   PubMed Web of Science ®Google Scholar
• Gutterman, J. U. 1994. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA 91:1198–1205.
   PubMed Web of Science ®Google Scholar
• Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425–479.
   PubMed Web of Science ®Google Scholar
• Hiller, S., A. Kohl, F. Fiorito, T. Herrmann, G. Wider, J. Tschopp, M. G. Grutter, and K. Wuthrich. 2003. NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain. Structure 11:1199–1205.
   PubMed Web of Science ®Google Scholar
• Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27.
   PubMed Web of Science ®Google Scholar
• Honda, R., and H. Yasuda. 2000. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19:1473–1476.
   PubMed Web of Science ®Google Scholar
• Jagus, R., B. Joshi, and G. N. Barber. 1999. PKR, apoptosis and cancer. Int. J. Biochem. Cell Biol. 31:123–138.
   PubMed Web of Science ®Google Scholar
• Jin, A., K. Itahana, K. O'Keefe, and Y. Zhang. 2004. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 24:7669–7680.
   PubMed Web of Science ®Google Scholar
• Jin, Y., H. Lee, S. X. Zeng, M. S. Dai, and H. Lu. 2003. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 22:6365–6377.
   PubMed Web of Science ®Google Scholar
• Joazeiro, C. A., and A. M. Weissman. 2000. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102:549–552.
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W., W. Wei, A. Greenway, and J. A. Trapani. 2000. Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene 19:6033–6042.
   PubMed Web of Science ®Google Scholar
• Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206–208.
   PubMed Web of Science ®Google Scholar
• Klein, C., and L. T. Vassilev. 2004. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 91:1415–1419.
   PubMed Web of Science ®Google Scholar
• Kulaeva, O. I., S. Draghici, L. Tang, J. M. Kraniak, S. J. Land, and M. A. Tainsky. 2003. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 22:4118–4127.
   PubMed Web of Science ®Google Scholar
• Lai, Z., K. V. Ferry, M. A. Diamond, K. E. Wee, Y. B. Kim, J. Ma, T. Yang, P. A. Benfield, R. A. Copeland, and K. R. Auger. 2001. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J. Biol. Chem. 276:31357–31367.
   PubMed Web of Science ®Google Scholar
• Lengyel, P. 1993. Tumor-suppressor genes: news about the interferon connection. Proc. Natl. Acad. Sci. USA 90:5893–5895.
   PubMed Web of Science ®Google Scholar
• Levy, D. E., and A. Garcia-Sastre. 2001. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 12:143–156.
   PubMed Web of Science ®Google Scholar
• Li, L., J. Liao, J. Ruland, T. W. Mak, and S. N. Cohen. 2001. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. USA 98:1619–1624.
   PubMedGoogle Scholar
• Li, M., C. L. Brooks, N. Kon, and W. Gu. 2004. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13:879–886.
   PubMed Web of Science ®Google Scholar
• Liepinsh, E., R. Barbals, E. Dahl, A. Sharipo, E. Staub, and G. Otting. 2003. The death-domain fold of the ASC PYRIN domain, presenting a basis for PYRIN/PYRIN recognition. J. Mol. Biol. 332:1155–1163.
   PubMedGoogle Scholar
• Liu, Y., M. Encinas, J. X. Comella, M. Aldea, and C. Gallego. 2004. Basic helix-loop-helix proteins bind to TrkB and p21Cip1 promoters linking differentiation and cell cycle arrest in neuroblastoma cells. Mol. Cell. Biol. 24:2662–2672.
   PubMedGoogle Scholar
• Ludlow, L. E. A., R. W. Johnstone, and C. J. Clarke. 2005. The HIN-200 family: More than interferon-inducible genes? Exp. Cell Res. 308:1–17.
   PubMedGoogle Scholar
• Marchetti, A., F. Buttitta, S. Girlando, P. Dalla Palma, S. Pellegrini, P. Fina, C. Doglioni, G. Bevilacqua, and M. Barbareschi. 1995. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J. Pathol. 175:31–38.
   PubMedGoogle Scholar
• Martin, K. J., E. Graner, Y. Li, L. M. Price, B. M. Kritzman, M. V. Fournier, E. Rhei, and A. B. Pardee. 2001. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc. Natl. Acad. Sci. USA 98:2646–2651.
   PubMed Web of Science ®Google Scholar
• McCann, A. H., A. Kirley, D. N. Carney, N. Corbally, H. M. Magee, G. Keating, and P. A. Dervan. 1995. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer 71:981–985.
   PubMed Web of Science ®Google Scholar
• Meek, D. W., and U. Knippschild. 2003. Posttranslational modification of MDM2. Mol. Cancer Res. 1:1017–1026.
   PubMed Web of Science ®Google Scholar
• Moller, M. B. 2003. Molecular control of the cell cycle in cancer: biological and clinical aspects. Dan. Med. Bull. 50:118–138.
   PubMedGoogle Scholar
• Montes de Oca Luna, R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203–206.
   PubMed Web of Science ®Google Scholar
• Mori, Y., J. Yin, A. Rashid, B. A. Leggett, J. Young, L. Simms, P. M. Kuehl, P. Langenberg, S. J. Meltzer, and O. C. Stine. 2001. Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Cancer Res. 61:6046–6049.
   PubMedGoogle Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857–860.
   PubMed Web of Science ®Google Scholar
• Picksley, S. M., and D. P. Lane. 1993. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15:689–690.
   PubMed Web of Science ®Google Scholar
• Pradhan, A., A. Mijovic, K. Mills, P. Cumber, N. Westwood, G. J. Mufti, and F. V. Rassool. 2004. Differentially expressed genes in adult familial myelodysplastic syndromes. Leukemia 18:449–459.
   PubMedGoogle Scholar
• Raffaella, R., D. Gioia, M. De Andrea, P. Cappello, M. Giovarelli, P. Marconi, R. Manservigi, M. Gariglio, and S. Landolfo. 2004. The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp. Cell Res. 293:331–345.
   PubMedGoogle Scholar
• Reed, J. C., K. Doctor, A. Rojas, J. M. Zapata, C. Stehlik, L. Fiorentino, J. Damiano, W. Roth, S. Matsuzawa, R. Newman, S. Takayama, H. Marusawa, F. Xu, G. Salvesen, A. Godzik, R. G. Group, and G. S. L. Members. 2003. Comparative analysis of apoptosis and inflammation genes of mice and humans. Genome Res. 13:1376–1388.
   PubMedGoogle Scholar
• Romeo, G., G. Fiorucci, M. V. Chiantore, Z. A. Percario, S. Vannucchi, and E. Affabris. 2002. IRF-1 as a negative regulator of cell proliferation. J. Interferon Cytokine Res. 22:39–47.
   PubMed Web of Science ®Google Scholar
• Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554–564.
   PubMed Web of Science ®Google Scholar
• Sandoval, R., J. Xue, M. Pilkinton, D. Salvi, H. Kiyokawa, and O. R. Colamonici. 2004. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J. Biol. Chem. 279:32275–32280.
   PubMedGoogle Scholar
• Sharpless, N. E., and R. A. DePinho. 1999. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9:22–30.
   PubMed Web of Science ®Google Scholar
• Sheikh, M. S., Z. M. Shao, A. Hussain, and J. A. Fontana. 1993. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res. 53:3226–3228.
   PubMed Web of Science ®Google Scholar
• Shiraishi, T., and P. E. Nielsen. 2004. Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates. Nucleic Acids Res. 32:4893–4902.
   PubMed Web of Science ®Google Scholar
• Silverman, R. H. 2003. Implications for RNase L in prostate cancer biology. Biochemistry 42:1805–1812.
   PubMed Web of Science ®Google Scholar
• Stad, R., N. A. Little, D. P. Xirodimas, R. Frenk, A. J. van der Eb, D. P. Lane, M. K. Saville, and A. G. Jochemsen. 2001. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2:1029–1034.
   PubMed Web of Science ®Google Scholar
• Stehlik, C., and J. C. Reed. 2004. The PYRIN connection: novel players in innate immunity and inflammation. J. Exp. Med. 200:551–558.
   PubMed Web of Science ®Google Scholar
• Stommel, J. M., N. D. Marchenko, G. S. Jimenez, U. M. Moll, T. J. Hope, and G. M. Wahl. 1999. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1660–1672.
   PubMed Web of Science ®Google Scholar
• Takaoka, A., S. Hayakawa, H. Yanai, D. Stoiber, H. Negishi, H. Kikuchi, S. Sasaki, K. Imai, T. Shibue, K. Honda, and T. Taniguchi. 2003. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516–523.
   PubMed Web of Science ®Google Scholar
• Theobald, D. L., R. M. Mitton-Fry, and D. S. Wuttke. 2003. Nucleic acid recognition by OB-fold proteins. Annu. Rev. Biophys. Biomol. Struct. 32:115–133.
   PubMedGoogle Scholar
• Tokino, T., S. Thiagalingam, W. S. el-Deiry, T. Waldman, K. W. Kinzler, and B. Vogelstein. 1994. p53 tagged sites from human genomic DNA. Hum. Mol. Genet. 3:1537–1542.
   PubMedGoogle Scholar
• Varambally, S., S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, D. Ghosh, K. J. Pienta, R. G. Sewalt, A. P. Otte, M. A. Rubin, and A. M. Chinnaiyan. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629.
   PubMed Web of Science ®Google Scholar
• Vilcek, J., and M. Feldmann. 2004. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci. 25:201–209.
   PubMed Web of Science ®Google Scholar
• Weber, J. D., L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1:20–26.
   PubMed Web of Science ®Google Scholar
• Wei, W., C. J. Clarke, G. R. Somers, K. S. Cresswell, K. A. Loveland, J. A. Trapani, and R. W. Johnstone. 2003. Expression of IFI 16 in epithelial cells and lymphoid tissues. Histochem. Cell Biol. 119:45–54.
   PubMedGoogle Scholar
• Wen, Y., D. H. Yan, B. Wang, B. Spohn, Y. Ding, R. Shao, Y. Zou, K. Xie, and M. C. Hung. 2001. p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. Cancer Res. 61:7142–7147.
   PubMedGoogle Scholar
• Xin, H., J. Curry, R. W. Johnstone, B. J. Nickoloff, and D. Choubey. 2003. Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene 22:4831–4840.
   PubMedGoogle Scholar
• Yang, H.-Y., Y.-Y. Wen, C.-H. Chen, G. Lozano, and M.-H. Lee. 2003. 14-3-3σ positively regulates p53 and suppresses tumor growth. Mol. Cell. Biol. 23:7096–7107.
   PubMed Web of Science ®Google Scholar
• Yeung, M. C., and A. S. Lau. 1998. Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells. J. Biol. Chem. 273:25198–25202.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., H. Wang, M. Li, S. Agrawal, X. Chen, and R. Zhang. 2004. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279:16000–16006.
   PubMed Web of Science ®Google Scholar